세계의 노르트립틸린 염산염 시장 규모는 예측기간인 2024년부터 2031년까지 2.3%의 연평균 복합 성장률(CAGR)로 확대될 전망이며, 2023년 2억 3,970만 달러에서 2031년에는 2억 8,752만 달러로 성장할 것으로 예측됩니다. 시장 성장의 배경에는 신경통 증가 및 우울증과 같은 기분 장애의 유병률 증가가 있습니다.
노르트립틸린은 시냅스 전 신경 세포막에 의한 노르 에피네프린과 세로토닌의 재 흡수를 억제하여 시냅스 내의 이들 신경 전달 물질의 농도를 증가시킵니다. 노르트립틸린은 아세틸콜린, 히스타민, 5-하이드록시트립타민의 활성도 억제합니다. 세계 여러 지역에서 우울증의 유병률이 상승하는 것은 시장 성장을 가속하는 주요 시장 동향 중 하나입니다. 예를 들어 세계보건기구(WHO)의 추정에 따르면 세계 성인 인구의 약 5%가 우울증을 앓고 있습니다. 우울증은 남성에 비해 여성에게 50% 더 많이 나타납니다. 아미트립틸린의 활성 대사산물인 노르트립틸린 염산염은 삼환계 항우울제로 작용하며 우울증 치료에 사용되기 때문에 우울증을 앓고 있는 사람의 증가는 시장에 유리한 성장 기회를 제공합니다.
신경병증성 통증을 앓고 있는 환자 증가는 또한 세계의 노르트립틸린 염산염 시장 규모를 끌어올리는 중요한 요인입니다. 노르트립틸린은 후근 신경절에서 비신경 위성 세포에서 발현되는 B2 아드레날린 수용체에 작용하는 노르아드레날린 수준을 증가시킴으로써 신경병증성 통증을 완화시킵니다. B2-아드레날린 수용체를 자극하면 신경 장애로 인한 TNFa 생산이 감소하고 신경 병성 통증이 완화됩니다. 노르트립틸린은 일반적으로 용액 또는 캡슐로서 경구 투여됩니다. 캡슐은 75mg, 50mg, 25mg, 10mg 등 다양한 강도로 입수 가능하며, 용액은 10mg/5mL(473mL)의 조성으로 입수 가능합니다. 따라서 신경병증성 통증을 앓고 있는 환자 증가는 노르트립틸린 염산염에 대한 수요를 증가시키고 통증 관리용 의약품의 생산을 촉진하고 시장에 유리한 성장 기회를 제공합니다.
본 보고서에서는 세계의 노르트립틸린 염산염 시장에 대해 조사했으며, 시장 개요와 함께 순도별, 형태별, 용도별, 지역별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.
Global nortriptyline hydrochloride market is projected to witness a CAGR of 2.3% during the forecast period 2024-2031, growing from USD 239.7 million in 2023 to USD 287.52 million in 2031F. The market growth is aided by increasing incidences of nerve pain and the rising prevalence of mood disorders such as depression.
Nortriptyline inhibits the reuptake of norepinephrine and serotonin by the presynaptic neuronal membrane, resulting in an increased concentration of these neurotransmitters in the synapse. Nortriptyline also inhibits the activity of acetylcholine, histamine, and 5-hydroxytryptamine. The increasing prevalence of depression in various regions around the globe is one of the major market trends that is fostering market growth. For instance, according to the estimates of the World Health Organization (WHO), approximately 5% of the adult global population suffers from depression. It is 50% more common in women as compared to men. This increase in the number of individuals suffering from depression will provide lucrative growth opportunities to the market as nortriptyline hydrochloride, an active metabolite of amitriptyline acts as a tricyclic antidepressant and is used for treating major depression.
The rise in incidences of individuals suffering from neuropathic pain is another major factor bolstering the global nortriptyline hydrochloride market size. Nortriptyline reduces neuropathic pain by increasing noradrenaline levels that act within the dorsal root ganglia on B2-adrenoceptors expressed by the non-neuronal satellite cells. Stimulating B2-adrenoceptors results in the reduced neuropathy-induced production of TNFa, thereby relieving neuropathic pain. Nortriptyline is usually administered orally as a solution or a capsule. The capsule is available in varying strengths including 75 mg, 50 mg, 25 mg, and 10 mg and the solution is available in the composition of 10mg/ 5mL (473 mL). Hence, due to the increasing cases of individuals suffering from neuropathic pain, the requirement for nortriptyline hydrochloride is rising to support the production of medication for pain management, thereby providing lucrative growth opportunities to the market.
Growing Prevalence of Depression Supports Global Nortriptyline Hydrochloride Market Growth
The nortriptyline hydrochloride treats depression by increasing the quantity of norepinephrine and serotonin in the brain, the substances that are responsible for regulating mood. Thus, supporting the market's growth by propelling the demand for nortriptyline hydrochloride. The dosage of the medication is based on the condition of the patient and their response to the treatment. The dose of the medication is directed at a lower range which is then increased gradually to reduce the risk of side effects associated with the medication.
The susceptibility of the contemporary population to depression is growing due to several factors including intense individual competitiveness, rising social failure, low social support, and increased inequality. For instance, according to the estimates of the World Health Organization (WHO), approximately 3.8% of the population suffers from depression. This includes 5% of the adult population of which 5.7% are older than 60 years. Nearly 280 million individuals across the globe are living with depression. Hence, this increase will augment the requirement for nortriptyline hydrochloride as the product belongs to a group of medications that are known as tricyclic antidepressants.
Increasing Incidences of Diabetic Neuropathy Boosts Global Nortriptyline Hydrochloride Market Demand
The presence of high blood glucose levels and fats, including triglycerides in blood due to diabetes can result in nerve damage causing diabetic neuropathy. High blood sugar levels can also cause damage to the blood vessels that provide the nerves with nutrients and oxygen. For instance, according to the estimates of the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 30% of the individuals suffering from diabetes have automatic neuropathy. This, in turn, is bolstering the requirement for nortriptyline hydrochloride to support the production of medication for managing diabetic neuropathy. Henceforth, augmenting the market demand in various regions across the globe.
Meanwhile, the rising consumption of food products with high amounts of sugar and carbonated beverages coupled with changing lifestyle patterns are increasing the number of individuals suffering from diabetes. This, in turn, is propelling the incidences of diabetic neuropathy, bolstering the product demand to ensure the production of appropriate medication to support the management of the condition. For instance, according to the projections of the International Diabetes Federation, by 2045, approximately 783 million people, 1 in 8 adults, will be living with diabetes. As the incidences of diabetes increase, the cases of diabetic neuropathy will also increase, thus augmenting the global nortriptyline hydrochloride market growth.
North America Accounts for Significant Market Share
The presence of a well-established healthcare sector and increasing investments by various pharmaceutical, healthcare, and biotechnology companies towards research and development activities is bolstering the demand for nortriptyline hydrochloride in various countries in North America. The increasing prevalence of depression in the region is further supporting the market expansion. For instance, according to the estimates of Mental Health America, more than 8% of American adults, approximately 21 million individuals are affected by depression. This increased prevalence coupled with the easy accessibility to various medications that help in treating depression are supporting the market growth as nortriptyline hydrochloride works as a tricyclic antidepressant. Therefore, the increasing incidences of individuals suffering from chronic pain is another major factor supporting the market expansion in the region, as the product finds applications in various medications that are used for treating chronic pain.
Rising Demand for More than 99% Nortriptyline Hydrochloride Boosts Market Growth
The increasing requirement for nortriptyline hydrochloride with more than 99% purity can be attributed to their rising demand by academic and research institutions and medicine manufacturing facilities in various regions across the globe. The pharmaceutical sector is significantly growing in various regions, for instance, according to the estimates of The Association of the British Pharmaceutical Industry, the pharmaceutical industry spends approximately USD 160 billion every year on research and development activities as the development of novel medications involves significant rates of failure. Due to such growing efforts and investments in medicine manufacturing, the requirement for nortriptyline hydrochloride will increase, thus propelling the growth of the market. The preference for nortriptyline hydrochloride with more than 99% purity can also be attributed to the high efficacy offered by the product as opposed to their counterparts, thus augmenting their demand, and supporting the expansion of the market.
Capsules Account for Significant Global Nortriptyline Hydrochloride Market Share
The expansion of the segment can be attributed to the higher bioavailability offered by the capsules as opposed to their counterparts, making them more effective than tablets. The nortriptyline hydrochloride capsules contain various inactive ingredients including sodium lauryl sulfate, colloidal silicon dioxide, pregelatinized starch, and magnesium stearate. For instance, the 75 mg, 50 mg, 25 mg, and 10 mg capsule shells contain titanium dioxide, gelatin, sodium lauryl sulfate, propylparaben, and methylparaben. They can also contain edetate calcium disodium, benzyl alcohol, silicon dioxide or sodium propionate, and butylparaben. The 75 mg, 25 mg, and 10 mg capsule shells also contain FD&C Blue No. 1 and D&C Yellow No. 10. The nortriptyline hydrochloride is usually prescribed for the smallest quantity of capsules with good patient management, to reduce the risk of overdose. Thus, the increased accessibility to nortriptyline hydrochloride capsules coupled with the rising awareness about mental health and depression are supporting the growth of the segment, thus boosting the market expansion.
Future Market Scenario (2024-2031F)
According to the global nortriptyline hydrochloride market analysis, the demand for nortriptyline hydrochloride will increase over the forecast period due to increasing research and development activities and utilization of the product for drug repurposing. Various studies are being conducted to evaluate the potential candidacy of nortriptyline hydrochloride for repurposing of drugs. For instance, according to an article published by researchers from the Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China, nortriptyline hydrochloride exhibits significant antitumor activities in both in-vitro and in-vivo. The product can inhibit gastric cancer by inducing oxidative stress and apoptosis. Conduction of such studies will bolster the requirement for nortriptyline hydrochloride over the forecast period by academic and research institutions augmenting the market demand.
Key Players Landscape and Outlook
The companies are undergoing continuous research and development. Furthermore, they are collaborating with other companies and organizations to support their R&D activities. Such initiatives will provide lucrative growth opportunities for the market as at times such efforts bring economies of scope that would not have been possible through organic growth. Thus, supporting the expansion of the global nortriptyline hydrochloride market.
In October 2023, Viatris Inc., one of the leading healthcare and pharmaceutical corporations, announced that they would be selling their Active Pharmaceutical Ingredients (API) business to Iquest Enterprises. The transaction includes a research and development lab and three manufacturing sites in Hyderabad, third-party API sales, and three manufacturing sites in Vizag.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work